Drug Profile
MLN 2222
Alternative Names: CAB-2; CMI-CAB-2; MLN2222; MLN2222 CAB-2Latest Information Update: 08 Apr 2009
Price :
$50
*
At a glance
- Originator Millennium Pharmaceuticals
- Developer XOMA
- Class Anti-inflammatories; Recombinant proteins
- Mechanism of Action Complement system protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Adult respiratory distress syndrome; Inflammation; Reperfusion injury
Most Recent Events
- 14 May 2008 Takeda acquires Millennium Pharmaceuticals
- 20 Mar 2006 XOMA has completed a phase I trial in the US
- 05 Aug 2005 This compound is still in active development - (BIO-2005)